Phio Pharmaceuticals Corp. Common Stock (PHIO)

About PHIO

Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center Phase 1b dose-escalating clinical trials; PH-894, an INTASYL compound that is designed to specifically silence BRD4, a protein that controls gene expression in both T ce…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

6

Website

phiopharma.com/

Fundamentals

1-day range

$1.08$1.16

Market cap

$12.31M

P/E (trailing)

—

P/E (forward)

-1.83

EPS (trailing)

$-1.49

Dividend yield

—

Beta

0.85

Avg. volume

606.1K

Dividend pay date

January 15, 2020

Forecasts

1 analyst ratings

Phio Pharmaceuticals Corp. Common Stock Competitors

Chosen by industry and closest market cap.

• PHIO

  Phio Pharmaceuticals Corp. Common Stock

  $1.13

  ▲ 0.45%
  Market cap $12.31MP/E —
  $0.8127$4.19
• BLRX

  BioLineRx Ltd. American Depositary Shares

  $2.61

  ▼ 5.43%
  Market cap $12.14MP/E Infinity
  $1.1$2.4
• CMMB

  Chemomab Therapeutics Ltd. American Depositary Share

  $2.7

  ▼ 0.74%
  Market cap $12.95MP/E —
  $1.35$3.63
• PBM

  Psyence Biomedical Ltd. Common Shares

  $4.21

  ▼ 3.44%
  Market cap $13.31MP/E —
  $1.92$216.37
• BFRG

  Bullfrog AI Holdings Inc. Common Stock

  $0.54

  ▼ 4.49%
  Market cap $10.96MP/E —
  $0.4251$2.04
• AEON

  AEON Biopharma Inc. Class A Common Stock

  $0.3095

  ▲ 5.27%
  Market cap $13.80MP/E —
  $0.1772$1.45
• AKTX

  Akari Therapeutics plc ADS

  $11.03

  ▲ 22.42%
  Market cap $14.14MP/E Infinity
  $3.02$49.6

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• HC Wainwright & Co. Reiterates Buy on Phio Pharmaceuticals, Maintains $14 Price Target
  benzinga · 8/26/2026
• Phio Pharmaceuticals Receives US Notice Of Allowance For Patent Covering PH-894, Further Strengthening Company's IP Portfolio
  Benzinga · 8/11/2026

Institutional Ownership

March 31, 2026

Total shares held

630.3K

Total value held

$702.5K

Institutional holders

23